All In Biotech

Drug Trial Radar · NCT07823322

A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy

A Phase 2 Study of INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy (NEXERA-204)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Dec 14, 2026

Primary completion

May 14, 2029

Study completion May 14, 2029

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Sep 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate INCA33890 in the treatment of circulating tumor DNA-positive stage II/III microsatellite stable colorectal cancer after curative resection and chemotherapy.

Conditions

  • CRC (Colorectal Cancer)

Interventions

  • INCA33890Drug

    INCA33890 will be administered at protocol defined dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Circulating tumor DNA (ctDNA) clearanceTime frame: 3 months

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • City of Hope Medical Center

    Duarte, California · Not yet recruiting

  • Oncura Health

    Glendale, California · Not yet recruiting

  • City of Hope Medical Center

    Irvine, California · Not yet recruiting

  • City of Hope - Chicago Cancer Center

    Zion, Illinois · Not yet recruiting

  • Maryland Oncology Hematology P.A.

    Rockville, Maryland · Not yet recruiting

  • The University of North Carolina At Chapel Hill

    Chapel Hill, North Carolina · Not yet recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Not yet recruiting

  • Tennessee Oncology, Pllc

    Nashville, Tennessee · Not yet recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Not yet recruiting

  • Texas Oncology Northeast Location

    Flower Mound, Texas · Not yet recruiting

  • Md Anderson Cancer Center

    Houston, Texas · Not yet recruiting

  • Texas Oncology

    Webster, Texas · Not yet recruiting

  • Virginia Cancer Specialists, Pc

    Fairfax, Virginia · Not yet recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Not yet recruiting

  • Pan American Center For Oncology Trials, Llc

    Ponce, Puerto Rico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.